Cresco Labs Gestione
Criteri Gestione verificati 2/4
Cresco Labs Il CEO è Charlie Bachtell, nominato in Feb2015, e ha un mandato di 11.33 anni. la retribuzione annua totale è $ 1.55M, composta da 32.2% di stipendio e 67.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.6% delle azioni della società, per un valore di CA$ 3.16M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6.7 anni e 9.5 anni.
Informazioni chiave
Charlie Bachtell
Amministratore delegato
US$1.6m
Compenso totale
| Percentuale dello stipendio del CEO | 32.18% |
| Mandato del CEO | 11.3yrs |
| Proprietà del CEO | 0.6% |
| Durata media del management | 6.7yrs |
| Durata media del Consiglio di amministrazione | 9.5yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento della narrazione • Jun 18
CL: Texas License And Expanded Ohio Stores Will Support Upside Skewed Profile
Analysts have nudged their fair value estimate for Cresco Labs stock from about CA$2.25 to roughly CA$2.35 per share, reflecting updated assumptions around discount rates, revenue growth, and future P/E expectations. What’s in the News for Cresco Labs Cresco Labs opened Sunnyside Aberdeen in Aberdeen, Ohio, its second Ohio dispensary opening in the past month, bringing its footprint to eight locations in the state and 74 nationally.Aggiornamento della narrazione • Jun 04
CL: Expanded Footprint And Texas License Will Support A More Upside Skewed Profile
Analysts trimmed their price target on Cresco Labs to CA$2.25 from CA$2.50, citing updated assumptions around revenue growth, discount rate, profit margin and future P/E that together support a slightly lower fair value estimate. What's in the News Cresco Labs opened Sunnyside Aberdeen in Aberdeen, Ohio, its second new Ohio dispensary in the past month, bringing the footprint to eight locations in the state and 74 nationally.Aggiornamento della narrazione • May 05
CL: Lower P/E Expectations Will Support A More Upside Skewed Profile
Analysts now see Cresco Labs trading closer to CA$2.25 rather than CA$2.50, reflecting updated views on fair value, growth assumptions, profitability, discount rate and future P/E expectations. Analyst Commentary Bearish analysts have adjusted their view on Cresco Labs, with a lower price target of CA$2.25 compared with the earlier CA$2.50 level.
Aggiornamento della narrazione • Apr 20
CL: Discount-Adjusted Outlook Will Support Future Upside From Speculative Buy Rating
Analysts have trimmed their CA$ price target on Cresco Labs from CA$2.50 to CA$2.25, reflecting updated expectations for the discount rate, profit margin and future P/E assumptions. Analyst Commentary The revised CA$2.25 price target signals that analysts are updating their view of Cresco Labs as they refresh discount rate, margin and P/E assumptions, rather than completely changing their stance on the business.Aggiornamento della narrazione • Apr 05
CL: Revised Outlook Will Support Future Upside From Speculative Buy Rating
Analysts have reduced their price target on Cresco Labs to CA$2.25 from CA$2.50, citing updated assumptions regarding fair value, discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts have adjusted their view on Cresco Labs by trimming the price target to CA$2.25 from CA$2.50 while maintaining a Speculative Buy stance, which reflects both perceived upside potential and meaningful execution risk.Aggiornamento della narrazione • Mar 22
CL: Lower P/E Assumptions Will Support A More Upside-Skewed Outlook
Analysts now see Cresco Labs' fair value as aligning with a trimmed CA$2.25 price target, down from CA$2.50. This reflects updated views on growth, margins and a lower future P/E assumption.Aggiornamento della narrazione • Mar 07
CL: Higher Future P/E Assumptions Will Shape A More Upside-Skewed Outlook
Analysts have lowered their price target on Cresco Labs to CA$2.25 from CA$2.50, reflecting updated views on revenue growth, profit margins, and a much higher assumed future P/E multiple. Analyst Commentary Bearish analysts are signaling a more cautious stance on Cresco Labs by trimming their price target to CA$2.25 from CA$2.50, even while still seeing speculative upside potential.Aggiornamento della narrazione • Feb 21
CL: Expanded Retail Footprint And Flexible Equity Program Will Support A More Optimistic Outlook
Analysts have revised their price target on Cresco Labs to CA$16.91 from CA$18.36, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. What's in the News Cresco Labs filed a follow on equity offering for up to CA$140 million of Subordinate Voting Shares through an at the market program, giving the company flexibility to raise capital over time (Key Developments).Articolo di analisi • Feb 12
Cresco Labs Inc. (CSE:CL) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless
Cresco Labs Inc. ( CSE:CL ) shares have had a horrible month, losing 29% after a relatively good period beforehand. The...Aggiornamento della narrazione • Feb 06
CL: Expanded Retail And EU Entry Will Support A More Optimistic Outlook
Analysts have lifted their price target on Cresco Labs to US$1.94 from US$1.51, citing revised assumptions around revenue growth, profit margins, discount rate, and a lower future P/E multiple as key drivers of the change. What's in the News Cresco Labs filed a follow on equity offering of up to C$140 million in subordinate voting shares through an at the market program, adding flexibility to raise capital as needed (Key Developments).Aggiornamento della narrazione • Jan 23
CL: New German Entry Will Support Future Upside
Analysts have nudged their price target for Cresco Labs higher, now implying fair value of about $2.40 per share versus roughly $2.36 previously. The change reflects updated views on revenue growth, profit margins and future P/E assumptions.Aggiornamento della narrazione • Jan 09
CL: German Entry And Higher Margins Will Support Future Upside
Analysts have raised their price target for Cresco Labs from US$2.30 to about US$2.36, reflecting updated views on the company’s profit margin outlook and a lower assumed future P/E multiple. What's in the News Cresco Labs launched Cresco branded flower in Germany, marking its first commercial entry into the European Union and extending its growth plans beyond the U.S. cannabis market (Key Developments).Aggiornamento della narrazione • Dec 15
CL: Expanded Retail And European Entry Will Support Stronger Profitability
Analysts have modestly raised their price target on Cresco Labs to reflect an updated fair value estimate of approximately 2.30 dollars, up from about 2.16 dollars previously, citing expectations for stronger revenue growth, improved profit margins, a slightly lower discount rate, and a more reasonable future earnings multiple. What's in the News Entered the European Union with the launch of Cresco branded flower in Germany, using the market as a testbed for broader international expansion beyond U.S. cannabis (Key Developments).Articolo di analisi • Nov 26
Cresco Labs Inc. (CSE:CL) Not Doing Enough For Some Investors As Its Shares Slump 37%
Unfortunately for some shareholders, the Cresco Labs Inc. ( CSE:CL ) share price has dived 37% in the last thirty days...Articolo di analisi • Nov 08
Here's Why Cresco Labs (CSE:CL) Is Weighed Down By Its Debt Load
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • Oct 12
Optimistic Investors Push Cresco Labs Inc. (CSE:CL) Shares Up 35% But Growth Is Lacking
Despite an already strong run, Cresco Labs Inc. ( CSE:CL ) shares have been powering on, with a gain of 35% in the last...Articolo di analisi • Sep 06
Is Cresco Labs Inc. (CSE:CL) Trading At A 49% Discount?
Key Insights Cresco Labs' estimated fair value is CA$3.23 based on 2 Stage Free Cash Flow to Equity Current share price...Articolo di analisi • Jul 31
Optimistic Investors Push Cresco Labs Inc. (CSE:CL) Shares Up 27% But Growth Is Lacking
Cresco Labs Inc. ( CSE:CL ) shareholders are no doubt pleased to see that the share price has bounced 27% in the last...Articolo di analisi • Jul 23
Cresco Labs (CSE:CL) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Articolo di analisi • Jun 15
Cresco Labs Inc.'s (CSE:CL) 30% Share Price Plunge Could Signal Some Risk
The Cresco Labs Inc. ( CSE:CL ) share price has fared very poorly over the last month, falling by a substantial 30...Articolo di analisi • May 01
Cresco Labs Inc.'s (CSE:CL) Shares Climb 31% But Its Business Is Yet to Catch Up
Cresco Labs Inc. ( CSE:CL ) shareholders would be excited to see that the share price has had a great month, posting a...
Nuova narrazione • Mar 29
Expanding Production In Illinois, Pennsylvania And Kentucky Will Meet Demand
Expansion in Illinois and Pennsylvania and entry into Kentucky's market aim to boost revenue growth and market share.Articolo di analisi • Mar 07
Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 27%
The Cresco Labs Inc. ( CSE:CL ) share price has fared very poorly over the last month, falling by a substantial 27...Articolo di analisi • Jan 31
Is Cresco Labs (CSE:CL) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Articolo di analisi • Dec 14
Cresco Labs Inc. (CSE:CL) May Have Run Too Fast Too Soon With Recent 28% Price Plummet
To the annoyance of some shareholders, Cresco Labs Inc. ( CSE:CL ) shares are down a considerable 28% in the last...Articolo di analisi • Oct 24
Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely
It's not a stretch to say that Cresco Labs Inc.'s ( CSE:CL ) price-to-sales (or "P/S") ratio of 0.8x right now seems...Articolo di analisi • Aug 11
Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Investors in Cresco Labs Inc. ( CSE:CL ) had a good week, as its shares rose 3.4% to close at CA$2.15 following the...Articolo di analisi • Jul 17
Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?
Key Insights Cresco Labs' estimated fair value is CA$3.60 based on 2 Stage Free Cash Flow to Equity Current share price...Articolo di analisi • Jun 19
Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Jun 19
Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
The Cresco Labs Inc. ( CSE:CL ) share price has fared very poorly over the last month, falling by a substantial 26...Articolo di analisi • Mar 16
Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41
The investors in Cresco Labs Inc. 's ( CSE:CL ) will be rubbing their hands together with glee today, after the share...Articolo di analisi • Mar 03
Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%
Cresco Labs Inc. ( CSE:CL ) shareholders won't be pleased to see that the share price has had a very rough month...Articolo di analisi • Jan 26
Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$134m |
| Dec 31 2025 | US$2m | US$500k | -US$135m |
| Sep 30 2025 | n/a | n/a | -US$52m |
| Jun 30 2025 | n/a | n/a | -US$46m |
| Mar 31 2025 | n/a | n/a | -US$84m |
| Dec 31 2024 | US$1m | US$492k | -US$74m |
| Sep 30 2024 | n/a | n/a | -US$67m |
| Jun 30 2024 | n/a | n/a | -US$172m |
| Mar 31 2024 | n/a | n/a | -US$155m |
| Dec 31 2023 | US$684k | US$450k | -US$176m |
| Sep 30 2023 | n/a | n/a | -US$339m |
| Jun 30 2023 | n/a | n/a | -US$234m |
| Mar 31 2023 | n/a | n/a | -US$211m |
| Dec 31 2022 | US$1m | US$450k | -US$212m |
| Sep 30 2022 | n/a | n/a | -US$65m |
| Jun 30 2022 | n/a | n/a | -US$326m |
| Mar 31 2022 | n/a | n/a | -US$318m |
| Dec 31 2021 | US$1m | US$450k | -US$320m |
| Sep 30 2021 | n/a | n/a | -US$360m |
| Jun 30 2021 | n/a | n/a | -US$73m |
| Mar 31 2021 | n/a | n/a | -US$105m |
| Dec 31 2020 | US$538k | US$450k | -US$102m |
| Sep 30 2020 | n/a | n/a | -US$76m |
| Jun 30 2020 | n/a | n/a | -US$98m |
| Mar 31 2020 | n/a | n/a | -US$64m |
| Dec 31 2019 | US$676k | US$350k | -US$43m |
Compensazione vs Mercato: La retribuzione totale di Charlie ($USD 1.55M ) è superiore alla media delle aziende di dimensioni simili nel mercato Canadian ($USD 895.18K ).
Compensazione vs guadagni: La retribuzione di Charlie è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Charlie Bachtell (46 yo)
11.3yrs
Mandato
US$1,554,019
Compensazione
Mr. Charles Bachtell, also known as Charlie, is Director of Chicagoland Chamber of Commerce. Mr. Bachtell serves as Co-Founder and Chief Executive Officer at Cresco Labs Inc. (formerly known as Cresco Labs...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 11.3yrs | US$1.55m | 0.60% CA$ 3.2m | |
| President | 2.3yrs | US$1.03m | 0.0027% CA$ 14.0k | |
| Co-Founder & Independent Director | no data | US$85.00k | 1.12% CA$ 5.9m | |
| Chief Financial Officer | 1.6yrs | US$534.46k | 0.019% CA$ 100.2k | |
| Chief Operating Officer | 5.3yrs | Nessun dato | Nessun dato | |
| Chief Information Officer | no data | Nessun dato | 0.081% CA$ 426.4k | |
| Senior Vice President of Corporate Development and Investor Relations | no data | Nessun dato | Nessun dato | |
| General Counsel | 8yrs | Nessun dato | 0.021% CA$ 108.0k | |
| Chief People Officer | 6.9yrs | Nessun dato | 0.066% CA$ 349.0k | |
| Senior VP of Operations | no data | Nessun dato | Nessun dato | |
| Executive Vice President of Operations | 8.4yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Cultivation | 6.4yrs | Nessun dato | Nessun dato |
6.7yrs
Durata media
48yo
Età media
Gestione esperta: Il team dirigenziale di CL è esperto e expertise (durata media dell'incarico 6.7 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 11.3yrs | US$1.55m | 0.60% CA$ 3.2m | |
| Co-Founder & Independent Director | 11.1yrs | US$85.00k | 1.12% CA$ 5.9m | |
| Independent Director | 6.4yrs | US$80.00k | 0.27% CA$ 1.4m | |
| Independent Director | 9.3yrs | US$90.00k | 0.34% CA$ 1.8m | |
| Chairman of the Board | 9.7yrs | US$95.00k | 0.063% CA$ 333.0k | |
| Independent Director | 6yrs | US$80.00k | 0.0054% CA$ 28.5k | |
| Independent Director | 9.5yrs | US$95.33k | 0.082% CA$ 432.7k |
9.5yrs
Durata media
68yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CL sono considerati esperti (durata media dell'incarico 9.5 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/30 15:04 |
| Prezzo dell'azione a fine giornata | 2026/06/30 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Cresco Labs Inc. è coperta da 13 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Russell Stanley | Beacon Securities Limited |